These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22619367)

  • 1. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease.
    Waterman M; Xu W; Dinani A; Steinhart AH; Croitoru K; Nguyen GC; McLeod RS; Greenberg GR; Cohen Z; Silverberg MS
    Gut; 2013 Mar; 62(3):387-94. PubMed ID: 22619367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease.
    Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A
    Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
    Lightner AL; Tse CS; Potter DD; Moir C
    J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics.
    Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT
    J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis.
    Schaufler C; Lerer T; Campbell B; Weiss R; Cohen J; Sayej W; Hyams J
    J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):421-4. PubMed ID: 22395189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.
    Lau C; Dubinsky M; Melmed G; Vasiliauskas E; Berel D; McGovern D; Ippoliti A; Shih D; Targan S; Fleshner P
    Ann Surg; 2015 Mar; 261(3):487-96. PubMed ID: 24950263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.
    Syed A; Cross RK; Flasar MH
    Am J Gastroenterol; 2013 Apr; 108(4):583-93. PubMed ID: 23481144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
    J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
    Oussalah A; Roblin X; Laharie D; Filippi J; Flamant M; Faure P; Phelip JM; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(8):854-63. PubMed ID: 19764940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
    Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
    Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
    Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
    Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.
    Shwaartz C; Fields AC; Sobrero M; Cohen BD; Divino CM
    J Gastrointest Surg; 2016 Sep; 20(9):1636-42. PubMed ID: 27405310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.